PURPOSE: Radiotherapy is commonly used to treat a majority of patients with head and neck cancers. The long-term radiation-induced reduction of saliva output significantly contributes to the posttreatment morbidity experienced by these patients. The purpose of this study was to test the ability of the stable-free radical Tempol (4-hydroxy-2,2,6,6-tetramethylpiperidine-N-oxyl), an established radioprotector, to prevent radiation-induced salivary hypofunction in mice. EXPERIMENTAL DESIGN: The heads of C3H mice were exposed to a range of single radiation doses with or without an i.p. injection of 275 mg/kg Tempol 10 min before treatment. Salivary gland output was assessed 8 weeks postirradiation. RESULTS: Radiation caused a dose-dependent reduction in salivary flow in this model. Tempol treatment alone significantly reduced radiation-induced salivary hypofunction. The combination of Tempol with mouth/nose shielding showed essentially complete radiation protection at 15 Gy and approximately 75% protection at 17.5 Gy. CONCLUSIONS: This study demonstrates for the first time that significant radioprotection of the salivary glands is possible with Tempol in C3H mice.
PURPOSE: Radiotherapy is commonly used to treat a majority of patients with head and neck cancers. The long-term radiation-induced reduction of saliva output significantly contributes to the posttreatment morbidity experienced by these patients. The purpose of this study was to test the ability of the stable-free radical Tempol (4-hydroxy-2,2,6,6-tetramethylpiperidine-N-oxyl), an established radioprotector, to prevent radiation-induced salivary hypofunction in mice. EXPERIMENTAL DESIGN: The heads of C3H mice were exposed to a range of single radiation doses with or without an i.p. injection of 275 mg/kg Tempol 10 min before treatment. Salivary gland output was assessed 8 weeks postirradiation. RESULTS: Radiation caused a dose-dependent reduction in salivary flow in this model. Tempol treatment alone significantly reduced radiation-induced salivary hypofunction. The combination of Tempol with mouth/nose shielding showed essentially complete radiation protection at 15 Gy and approximately 75% protection at 17.5 Gy. CONCLUSIONS: This study demonstrates for the first time that significant radioprotection of the salivary glands is possible with Tempol in C3H mice.
Authors: Lyudmila G Burdelya; Anatoli S Gleiberman; Ilia Toshkov; Semra Aygun-Sunar; Meghana Bapardekar; Patricia Manderscheid-Kern; David Bellnier; Vadim I Krivokrysenko; Elena Feinstein; Andrei V Gudkov Journal: Int J Radiat Oncol Biol Phys Date: 2011-10-14 Impact factor: 7.038
Authors: Arjan Vissink; James B Mitchell; Bruce J Baum; Kirsten H Limesand; Siri Beier Jensen; Philip C Fox; Linda S Elting; Johannes A Langendijk; Robert P Coppes; Mary E Reyland Journal: Int J Radiat Oncol Biol Phys Date: 2010-11-15 Impact factor: 7.038
Authors: Aviram Mizrachi; Ana P Cotrim; Nora Katabi; James B Mitchell; Marcel Verheij; Adriana Haimovitz-Friedman Journal: Radiat Res Date: 2016-07-26 Impact factor: 2.841
Authors: Julianne M Pollard; Julio S Reboucas; Armando Durazo; Ivan Kos; Francesca Fike; Moeen Panni; Edith Butler Gralla; Joan Selverstone Valentine; Ines Batinic-Haberle; Richard A Gatti Journal: Free Radic Biol Med Date: 2009-04-21 Impact factor: 7.376
Authors: A Karliczek; C J Zeebregts; D A Benaron; R P Coppes; T Wiggers; G M van Dam Journal: Int J Colorectal Dis Date: 2008-07-16 Impact factor: 2.571
Authors: Benjamin P Soule; Fuminori Hyodo; Ken-Ichiro Matsumoto; Nicole L Simone; John A Cook; Murali C Krishna; James B Mitchell Journal: Free Radic Biol Med Date: 2007-03-12 Impact factor: 7.376